在阿尔茨海默病的不可修改和可修改的风险因素上,miR-155的发病因子
Jia-Jia Liu1,2, Yun-Fan Long3, Peng Xu4
1Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Alzheimer's research & therapy
|July 14, 2023
概括
微RNAs (miRNAs) 是阿尔茨海默病 (AD) 进展的关键. 作为一种促炎调解物,米R-155会影响神经炎症,并可能为阿尔茨海默病提供新的诊断和治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是认知和行为缺陷.
- 阿尔茨海默病的确切病因尚不清楚,尽管年龄,遗传和血管因素都与此有关.
- 微RNA (miRNA) 是小型非编码RNA,调节基因表达,并显示出作为疾病生物标志物的潜力.
研究的目的:
- 审查miR-155在阿尔茨海默氏症病原发生中的作用.
- 探索miR-155在AD中的作用背后的生物机制.
- 突出miR-155作为阿尔茨海默病诊断和治疗的潜在目标.
主要方法:
- 文献综述侧重于miR-155和阿尔茨海默病.
- 对研究神经炎症中miRNA调节的研究进行分析.
- 检查miR-155对β-粉样蛋白和tau病理学的影响.
主要成果:
- 在神经炎症中,米R-155起到促炎媒介的作用.
- 在阿尔茨海默氏症中,MiR-155与β-粉样和tau病理的进展有关.
- 微RNA在体液中相对稳定,支持它们作为生物标记物的使用.
结论:
- MiR-155在导致阿尔茨海默病的炎症过程中起着重要作用.
- 了解miR-155的机制为阿尔茨海默病的新诊断和治疗策略提供了潜力.
- 对miR-155的进一步研究可能会导致管理阿尔茨海默病的创新方法.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.3K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
899
相关概念视频
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
01:30Coronary Artery Disease I: Introduction
25
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
25
01:30Atherosclerosis I: Introduction
11
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
11